This web page offers an overview of respiratory syncytial virus and parainfluenza viruses, detailing disease burden, virology, and vaccines from a global perspective. The annotated text included provides links to additional …

This article, published in Immunological Reviews, provides an overview of the barriers that have challenged and delayed the development of vaccines against respiratory syncytial virus (RSV) and identifies opportunities that could help overcome these …

There is currently no approved respiratory syncytial virus (RSV) vaccine, and the goal of preventing RSV-associated illness in the general population remains unmet. The authors of this article, published in Human Vaccines, discuss the challenges …

In studies conducted in the 1960s, children previously immunized with a formalin-inactivated respiratory syncytial virus (RSV) vaccine (FI-RSV) developed a greater incidence and severity of pulmonary disease during subsequent natural RSV infection …

This article, published in The Journal of Infectious Diseases, details a preclinical study evaluating the ability of a humanized monoclonal antibody, MEDI-493 (later named palivizumab and marketed at Synagis®), to recognize a conserved …

In the 1960s a respiratory syncytial virus (RSV) vaccine was evaluated in infants and young children. Vaccinees who received formalin-inactivated RSV during early infancy developed more serious lower-respiratory-tract disease when infected with the …

The authors of this study, published in Vaccine, compared formalin-inactivated (FI) RSV, purified F glycoprotein in alum, and RSV infection (intranasal) for their immunogenicity, efficacy, and ability to enhance pulmonary histopathology during RSV …

This article, published in the American Journal of Epidemiology, describes a study that evaluated altered clinical reactivity to a formalin-inactivated respiratory syncytial virus (RSV) vaccine candidate administered to healthy infants and children …

This article, published in BMC Public Health, summarizes the results of a literature review and an expert opinion exercise to evaluate the best course of protection against respiratory syncytial virus (RSV) for children in the developing world, …

This article, published the American Journal of Epidemiology, describes a field study conducted in California, United States, that evaluated two formalin inactivated respiratory virus vaccines, a respiratory syncytial virus (RSV) vaccine and a …

This article, published in The Lancet, describes research to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to respiratory syncytial virus (RSV) in children younger than five years …

This article, published in Expert Review of Vaccines, summarizes the proceedings from the 7th International Respiratory Syncytial Virus (RSV) Symposium, which convened approximately 200 clinicians, scientists, and industry representatives from …

This fact sheet outlines PATH's work on vaccines and immunization. Topic areas include developing affordable vaccines, designing innovative vaccine technologies, and expanding uptake of existing vaccines. These efforts reduce the burden of malaria, …

This comprehensive report includes expert articles on a variety of vaccine-related topics and updates on vaccine research for specific infectious diseases, such as influenza, malaria, respiratory syncytial virus, and rotavirus.

This article, published in Vaccine, discusses the advantages and disadvantages of maternal immunization to augment the protective effect of maternal antibody against many viral diseases in the young infant. The authors also present more specific …

This web page from the Vaccine Resource Library provides a link to information about PATH's work on respiratory syncytial virus (RSV) as well as general information about RSV and a snapshot of the current RSV vaccine landscape.

The only specific treatment available today against human respiratory syncytial virus (hRSV) is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe …

Respiratory syncytial virus (RSV) is responsible for serious respiratory disease in young infants. The authors of this article, published in The Pediatric Infectious Disease Journal, discuss the importance of maternal antibody in the immunity …

This fact sheet highlights PATH's work to develop a vaccine against respiratory syncytial virus (RSV) with the potential to help control RSV in the developing world through prevention.

This fact sheet provides an overview of the causes, means of transmission, symptoms, risk factors, treatment, prevention, and economic costs of pneumonia. Also outlined is the World Health Organization's action plan to prevent and treat pneumonia, …

The authors of this article, published in Expert Review of Anti-infective Therapy, discuss how pregnancy may provide a unique window of opportunity for interventions aimed at preventing severe respiratory syncytial virus (RSV) infection in the …

This article, published in Advances in Therapy, provides an overview of the pathogenesis of respiratory syncytial virus (RSV), the historical challenges facing RSV vaccine development, and current technologies being explored to prevent RSV disease. …

This article, published in Advances in Therapy, reviews the development and use of palivizumab, the only drug approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease. Palivizumab is a monoclonal antibody that …

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global …

This article, published in the American Journal of Epidemiology, details studies conducted to determine the ability of a formalin inactivated vaccine candidate to protect against respiratory syncytial virus (RSV) disease. Results from the study …